IBUPROFEN AND FAMOTIDINE Drug Patent Profile
✉ Email this page to a colleague
When do Ibuprofen And Famotidine patents expire, and when can generic versions of Ibuprofen And Famotidine launch?
Ibuprofen And Famotidine is a drug marketed by Alkem Labs Ltd, Ascent Pharms Inc, and Teva Pharms Usa. and is included in three NDAs.
The generic ingredient in IBUPROFEN AND FAMOTIDINE is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ibuprofen And Famotidine
A generic version of IBUPROFEN AND FAMOTIDINE was approved as famotidine; ibuprofen by ENDO OPERATIONS on March 22nd, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IBUPROFEN AND FAMOTIDINE?
- What are the global sales for IBUPROFEN AND FAMOTIDINE?
- What is Average Wholesale Price for IBUPROFEN AND FAMOTIDINE?
Summary for IBUPROFEN AND FAMOTIDINE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Clinical Trials: | 6 |
| Patent Applications: | 42 |
| What excipients (inactive ingredients) are in IBUPROFEN AND FAMOTIDINE? | IBUPROFEN AND FAMOTIDINE excipients list |
| DailyMed Link: | IBUPROFEN AND FAMOTIDINE at DailyMed |
Recent Clinical Trials for IBUPROFEN AND FAMOTIDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duke University | Phase 4 |
| Horizon Pharma Ireland, Ltd., Dublin Ireland | Phase 4 |
| Pediatric Rheumatology Collaborative Study Group | Phase 4 |
Pharmacology for IBUPROFEN AND FAMOTIDINE
| Drug Class | Histamine-2 Receptor Antagonist Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors Histamine H2 Receptor Antagonists |
US Patents and Regulatory Information for IBUPROFEN AND FAMOTIDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Labs Ltd | IBUPROFEN AND FAMOTIDINE | famotidine; ibuprofen | TABLET;ORAL | 211890-001 | Aug 3, 2021 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ascent Pharms Inc | IBUPROFEN AND FAMOTIDINE | famotidine; ibuprofen | TABLET;ORAL | 216814-001 | Mar 15, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa | IBUPROFEN AND FAMOTIDINE | famotidine; ibuprofen | TABLET;ORAL | 211278-001 | Oct 29, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
